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RESUMO
Denervação Simpática Renal para o  
Controle da Hipertensão Arterial Resistente
Introdução: A hipertensão arterial sistêmica afeta mais de 1,2 
milhão de pessoas no mundo. Apenas 35% dos pacientes hiper-
tensos têm valores de pressão arterial controlados. Recentemente 
a denervação simpática renal (DSR) tem demonstrado diminuir 
significativamente os valores de pressão arterial nos pacientes 
com hipertensão arterial sistêmica resistente. Métodos: Estudo 
prospectivo, de braço único, observacional, multicêntrico, in-
cluindo pacientes consecutivos submetidos a DSR. O objetivo 
primário foi avaliar os níveis da pressão arterial sistólica aos 
30 dias de seguimento. O objetivo secundário foi determinar 
a ocorrência de qualquer evento adverso relacionado com o 
procedimento. Resultados: Foram incluídos os primeiros 20 
pacientes submetidos a DSR. A média de pressão arterial antes 
do procedimento foi de 171,6/93,2 ± 15,5/11,3 mmHg, com 
média de uso de 4,1 ± 1,5 fármacos anti-hipertensivos por 
paciente. A taxa de sucesso foi de 95%, tendo sido aplicadas 
11,1 ± 1,9 ablações por paciente. Foi observada diminuição 
média de 29 ± 21 mmHg (P = 0,009) na pressão arterial 
sistólica 30 dias após o procedimento. Não houve complicação 
associada ao procedimento. Conclusões: A DSR por cateter em 
pacientes da prática clínica diária diminuiu significativamente 
os valores de pressão arterial. Em nossa experiência, a DSR 
demonstrou ser factível e segura.
DESCRITORES: Hipertensão. Rins. Simpatectomia. Cateteres.
ABSTRACT
Background: Systemic arterial hypertension affects over 1.2 
million people worldwide. Only 35% of hypertensive patients 
have controlled blood pressure levels. Renal sympathetic 
denervation (RSD) has shown to significantly decrease blood 
pressure levels in patients with resistant systemic hypertension. 
Methods: Prospective, single arm, observational, multicenter study 
including consecutive patients undergoing RSD. The primary 
endpoint was to assess systolic blood pressure levels at the 
30-day follow-up. The secondary endpoint was to determine 
the presence of procedure-related adverse events. Results: The 
first 20 patients undergoing RSD were included. The average 
blood pressure prior the procedure was 171.6/93.2 ± 15.5/ 
11.3 mmHg, with the use of 4.1 ± 1.5 antihypertensive drugs 
per patient. Success rate was 95%, and 11.1 ± 1.9 ablations 
were performed per patient. A systolic blood pressure decrease 
of 29 ± 21 mmHg (P = 0.009) was observed 30 days after the 
procedure. There were no procedure-related complications. 
Conclusions: Catheter-based RSD in daily clinical practice 
patients significantly decreased blood pressure levels. In our 
experience, RSD proved to be feasible and safe.
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S ystemic arterial hypertension (SAH) affects over 1.2 million people worldwide, with a prevalence of 28% in the adult population.1,2 The consequences 
and progressive damage of SAH on target organs reduce 
patient survival, accounting for half of coronary and 
cerebrovascular events.3,4
Adequate control of SAH reduces the occurrence 
of adverse events. A 5 mmHg reduction in the systolic 
blood pressure is associated with a 10% decrease in 
relative risk of death from cerebrovascular causes and 
acute coronary syndrome. Conversely, a 20 mmHg 
increase in systolic blood pressure doubles the risk of 
mortality from cardiovascular causes.5 However, only 
35% of hypertensive patients have blood pressure 
values within the targets proposed by the guidelines,5 
in most cases due to poor adherence to prescribed 
treatment, suboptimal treatment, or secondary causes 
of SAH. However, approximately 10% of patients with 
appropriate use of three or more antihypertensive drugs 
do not manage to control their blood pressure levels; 
this group of patients, known as resistant hypertensive 
patients, have a high risk for the occurrence of adverse 
cardiovascular events.6
In the resistant hypertensive population, studies 
using microneurography and measurement of blood 
catecholamines demonstrated the participation of the 
sympathetic nervous system in the genesis and main-
tenance of SAH.79 Surgical sympathectomy was shown 
to be effective in reducing blood pressure in patients 
with resistant SAH; however, this technique was aban-
doned due to high rates of complications.10-12 More 
recently, a less invasive approach with percutaneous 
renal sympathetic denervation performed by applying 
radiofrequency to the renal artery wall was shown to 
decrease adrenergic tone, release of norepinephrine, 
and blood pressure.13 Catheter-guided (Symplicity, Ard-
ian Medtronic – Minneapolis, USA) renal sympathetic 
denervation was tested in the clinical trials Symplicity 
HTN-1-first-in-man and Symplicity HTN-2, presenting 
a significant and sustained decrease in systolic blood 
pressure.13,14 Recently, this system was made available 
for clinical use in Venezuela, initiating the authors’ 
experience with this procedure.
This study aimed to describe the characteristics 
of patients undergoing renal sympathetic denervation, 
as well as to evaluate the efficacy and safety of the 
procedure in daily clinical practice.
METHODS
Renal sympathetic denervation system
The components of the renal sympathetic denerva-
tion system are the Symplicity catheter and radiofre-
quency generator. The generator consists of two parts: 
the console and the pedal (Figure 1). The generator 
produces energy through radiofrequency, following a 
predetermined algorithm. During the radiofrequency 
application, voltage, temperature, and impedance of the 
application point on the renal artery are continuously 
monitored and controlled. The maximum voltage is 8 
W, and the system generates energy with impedances 
between 20 ohms and 500 ohms. The Symplicity cath-
eter, compatible with 6 Fr, applies radiofrequency energy 
to the renal artery wall. It comprises the handle lever 
and a flexible portion, 108 cm long, with a platinum 
monopolar electrode at the tip, with two radiopaque 
marks 5 mm apart from each other. By manipulating 
the handle lever, the catheter tip can be flexed and/or 
rotated to reach the correct position for the application 
of radiofrequency (Figure 2).
Procedure
An abdominal aortography was performed by 
femoral approach to assess the renal arteries and the 
technical feasibility of the procedure. Subsequently, 
the renal arteries were selectively catheterized, and the 
Symplicity catheter was advanced within the vessel. 
Four to eight ablations were applied from the distal 
to the proximal portion, 5 mm apart, with duration 
of 120 seconds in both renal arteries (Figure 3). Each 
radiofrequency application has a maximum of 8 W and 
increases in impedance and temperature are controlled 
Figure 1 – Radiofrequency generator of the Symplicity system.
Figure 2 – Symplicity Catheter.
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by the system in order to avoid tissue injury due to 
overheating. All patients were anticoagulated with un-
fractionated heparin (70 U/kg until an activated clotting 
time > 250 s was attained) during the procedure, and 
analgesia with benzodiazepines and opioids was used 
for pain control.
Study Design
This was a prospective, single-arm, observational 
multicenter study that included consecutive patients 
undergoing renal sympathetic denervation between 
March and December 2012 at three centers in Venezu-
ela. The primary outcome was the decrease of systolic 
blood pressure at 30 days of follow-up. The secondary 
outcome was the occurrence of any procedure-related 
adverse event.
The criteria for patient inclusion were: age > 18 
years with resistant SAH, defined as systolic blood 
pressure > 160 mmHg despite adequate use of three or 
more antihypertensive agents (at least one diuretic), or 
patients taking > four antihypertensive medications. The 
assessment of renal artery anatomy was recommended 
before the procedure using renal artery Doppler and/or 
imaging studies (computed tomography [CT] or magnetic 
resonance imaging [MRI]) or aortography.
Patients with glomerular filtration rate < 45 mL/
min/1.73 m² (calculated by the Cockcroft-Gault for-
mula),15 renal artery < 4 mm in diameter, < 20 mm in 
length, previous interventions in renal arteries, renal 
artery stenosis, and acute coronary syndrome or stroke 
< six months were excluded. Procedural success was 
defined as attaining the procedure in both renal arteries 
without procedure-related complications. 
Patient follow-up was performed by their respective 
attending physicians, who were instructed not to modify 
the antihypertensive treatment, if clinically possible, 
within the first 30 days after the procedure, and to 
report an average of three blood pressure measure-
ments obtained at the office at 30 days of follow-up, 
according to the recommended guidelines.5
This study was performed in accordance with the 
Declaration of Helsinki and the principles of good clini-
cal practice. All patients signed an informed consent 
before the procedure.
Statistical analysis
Quantitative variables are shown as means and 
standard deviations, and qualitative variables are shown 
as percentages. Student’s t-test was used to compare 
quantitative variables. A P-value < 0.05 was considered 
significant. Statistical analysis was performed with SPSS 
software, version 16.0 (SPSS Inc., Chicago, USA).
RESULTS
This analysis included the first 20 patients undergo-
ing renal sympathetic denervation. The mean age was 
56 ± 12.1 years, 55% were females, and 55% were 
whites. Blood pressure (BP) before the procedure was 
171.6/93.2 ± 15.5/11.3 mmHg, using 4.1 ± 1.5 anti-
hypertensive drugs per patient (Table 1).
Regarding the characteristics of the procedure, suc-
cess rate was 95%; 11.1 ± 1.9 ablations were applied 
per patient, 5.7 ± 1.3 in the right renal artery and 5.5 
± 2.8 in the left renal artery, and the mean decrease 
in impedance was 15.2 ± 1.9 ohms (Table 2).
Regarding the primary outcome, a decrease of 29 
± 21 mmHg (P = 0.009) was observed in the systolic 
blood pressure 30 days after the procedure (Figure 4). 
Regarding the secondary safety outcome, there were no 
complications related to the procedure or the adverse 
events after 30 days of follow-up. Among the studied 
Figure 3 – Renal sympathetic denervation procedure. In A, abdominal aortography showing the anatomical viability of the procedure. In B, left renal 
artery with the Symplicity catheter positioned at the site of the first ablation.
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population, 80% had a decrease of at least 10 mmHg 
in systolic blood pressure, and 68% of patients had 
blood pressure values within the targets proposed by 
the guidelines.5
DISCUSSION
In the initial experience with the percutaneous 
renal sympathetic denervation system for the control of 
resistant hypertension, the authors observed a significant 
decrease in systolic blood pressure after 30 days. There 
were no complications related to the procedure.
Symplicity HTN-1, a single-arm trial that included 
45 patients undergoing renal sympathetic denervation, 
observed a decrease of 14 mmHg and 22 mmHg at 
30 days and six months of follow-up, respectively.13 
Subsequently, the Symplicity HTN-2 trial randomized 
106 patients with resistant SAH, in which the group 
allocated for renal sympathetic denervation had a BP 
of 178/96 mmHg with the use of 5.2 antihypertensive 
medications. Six months after the procedure, a significant 
decrease of 32 mmHg was observed in the group submit-
ted to renal sympathetic denervation, when compared 
with the clinical treatment group.14 In the scenario of 
real-world clinical practice, the Venezuelan Symplicity 
registry presented a decrease of 34 mmHg at 30 days 
of follow-up.16 In the present group, the decrease in 
BP at 30 days was 29 ± 21 mmHg, consistent with in 
the results of the Symplicity HTN-1 and HTN-2 trials 
and the Venezuelan Symplicity registry.13,14,16
TABLE 1 
Baseline clinical characteristics
Variable n = 20
Age, years 56 ± 121
Female gender, % 55
Body mass index, Kg/m2 30.2 ± 4.8
White, % 55
Obesity, % 30
Diabetes mellitus, % 45
Using insulin 15
Dyslipidemia, % 50
Smoking, % 5
Previous stroke, % 15
Creatinine clearance, mL/min/1.73 m2 87 ± 38
Pre-procedure blood pressure, mmHg
Systolic 171.6 ± 15.5
Diastolic 93.2 ± 11.3
Number of medication per patient 4.1 ± 1.5
Antihypertensive medications, %
Angiotensin converting enzyme 
inhibitors 
30
Angiotensin receptor blocker II 80
Beta-blocker 80
Diuretics 95
Calcium channel blocker 50
Centrally-acting sympatholytic 30
Renin inhibitor 5
TABLE 2  
Characteristics of the procedure
Variable n = 20
Success, % 95
Number of ablations per patient 11.1 ± 1.9
Number of ablations – right renal artery 5.7 ± 1.3
Number of ablations – left renal artery 5.5 ± 2.8
Decrease in impedance, ohms 15.2 ± 1.9
Analgesia,%
Morphine 20
Fentanyl 90
Midazolam 50
Propofol 60
Figure 4 – Decrease in systolic and diastolic blood pressure 30 days 
after the procedure. SBP, systolic blood pressure; DBP, diastolic blood 
pressure.
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Regarding safety, the complication rates during the 
procedure are low, mainly due the guide-catheter hand-
ling during renal artery catheterization. In the Symplicity 
HTN-1 trial, among the 45 treated patients, one had re-
nal artery dissection during catheterization with no need 
for additional treatment.13 In the Symplicity HTN-2 trial, 
there were no major adverse events and only one patient 
had lower back pain, which resolved spontaneously after 
30 days, and 13% of the cases had bradycardia during 
the procedure, which was successfully reversed using 
atropine.14 It is important to emphasize that, although 
this is the initial phase of the learning curve with the 
study device, procedure-related adverse events were not 
observed. Except for one case in which it was not pos-
sible to catheterize the renal artery due to extreme aortic 
tortuosity, all other cases were successful.
Renal sympathetic denervation has been shown an 
additional benefit besides the lowering of blood pressure. 
Brandt et al.17 demonstrated a significant reduction in 
left ventricular mass and improved diastolic function 
in patients undergoing renal sympathetic denervation. 
It is noteworthy that such findings were independent 
from the reduction in blood pressure.
Mahfoud et al.18 evaluated the effect of renal 
sympathetic denervation in diabetic patients, finding, 
at the three-month follow-up, a decrease in fasting 
glucose levels, from 118 ± 3.4 ± mg/dL to 108 ± 3.8 
mg/dL (P = 0.039); insulin levels, from 20.8 ± 3  IU/
mL to 9.3 ± 2.5 IU/mL (P = 0.006); and C peptide, 
from 5.3 ± 0.6 ng/mL to 3 ± 0.9  ng/mL (P = 0.002). 
These findings suggest that renal sympathetic denerva-
tion, in addition to lowering blood pressure, improves 
glucose metabolism and insulin sensitivity. Currently, 
new renal sympathetic denervation effects are being 
tested on heart failure, sleep apnoea, atrial fibrillation, 
and pulmonary hypertension.
Study limitations
The main limitations of this study were the small 
sample size and the fact that it was an observational 
study; therefore, it is necessary to confirm its findings 
in larger populations and, preferably, in a randomized 
fashion. However, the results were similar to those 
observed in the largest recently published studies,13,14 
which confers reliability to the present findings. Clinical 
follow-up of patients was performed by their attending 
physicians, who, despite strictly instructed not to modify 
the antihypertensive treatment within 30 days and to 
report any complaint or adverse effect, may have failed 
to follow such recommendations. Follow-up was con-
ducted through mean blood pressure measured at the 
office, instead of 24-hour ambulatory blood pressure 
monitoring, a method that presents a better correlation 
with target-organ damage.19 Finally, although the results 
related to the decrease in BP values are promising, late 
follow-up is essential to verify the maintenance of these 
acquired benefits.
CONCLUSIONS
In this observational study, renal sympathetic 
denervation guided by Symplicity catheter promoted 
decrease in systolic blood pressure in patients with 
resistant hypertension. This initial experience was shown 
to be safe, with no intraprocedure-related adverse events 
and at the 30-day follow-up.
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